PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)
- Resource Type
- Abstract
- Source
- In
Value in Health 2006 9(6):A282-A283 - Subject
Contributed Poster Presentations - Language
- ISSN
- 1098-3015